芦曲泊帕单药治疗环孢素A难治性输血依赖型非重型再生障碍性贫血的疗效与安全性
回顾性分析12例接受芦曲泊帕单药治疗的环孢素A难治性输血依赖型非重型再生障碍性贫血患者,中位治疗4个月,中位随访8个月。第3、6个月及随访期末OR率分别为50.0%、58.3%、50.0%,CR率分别为8.3%、16.7%、16.7%。不良反应均为Ⅰ级,发生率25.0%,未见克隆演变或死亡。
要点
- 芦曲泊帕单药治疗CsA难治性TD-NSAA的OR率为50.0%~58.3%,CR率为8.3%~16.7%。
- OR中位起效时间2个月,CR中位起效时间4个月。
- 不良反应均为Ⅰ级,发生率25.0%,未见克隆演变或死亡。
核心结论
- 芦曲泊帕对环孢素A难治性输血依赖型非重型再生障碍性贫血患者有效且耐受性良好。
研究设计与样本
- 回顾性分析12例接受芦曲泊帕单药治疗的环孢素A难治性输血依赖型非重型再生障碍性贫血患者。
主要发现
- 第3个月、第6个月及随访期末的OR率分别为50.0%、58.3%和50.0%,OR中位起效时间2(1~4)个月。
- 第3个月、第6个月及随访期末的CR率分别为8.3%、16.7%和16.7%,CR中位起效时间4(2~5)个月。
- 不良反应均为Ⅰ级,发生率为25.0%。
- 随访期间1例停药后未能维持OR,复发率14.3%;未见克隆演变或死亡。
局限性
- 本研究为回顾性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study retrospectively analyzed 12 patients with transfusion-dependent, non-severe aplastic anemia (TD-NSAA) refractory to cyclosporine A (CsA) , who were treated with lusutrombopag monotherapy. These patients either had a variety of chronic comorbidities or medication-related risks, or they were unresponsive to or intolerant of other thrombopoietin receptor agonists (TPO-RA) . The median treatment duration with lusutrombopag was 4 months (range: 3-11 months) , while the median follow-up period was 8 months (range: 6-11 months) . The overall response (OR) rates at months 3, 6, and the end of follow-up were 50.0%, 58.3%, and 50.0%, respectively, with a median time to OR of 2 months (range: 1-4 months) . Complete response (CR) rates were 8.3%, 16.7%, and 16.7% at the same time points, with a median time to CR of 4 months (range: 2-5 months) . Adverse events were all Grade 1, with an incidence rate of 25.0%. During follow-up, one patient experienced a loss of OR after discontinuing treatment, with a relapse rate of 14.3%; no clonal evolution or mortality was observed. These findings suggest that lusutrombopag is both effective and well-tolerated in CsA-refractory TD-NSAA patients and represents a promising therapeutic option for those with poor treatment tolerability. 回顾性分析12例接受芦曲泊帕单药治疗的环孢素A(CsA)难治性输血依赖型非重型再生障碍性贫血(TD-NSAA)患者,全部患者均伴有多种慢性基础疾病或药物相关风险,或对其他血小板受体激动剂(TPO-RA)无效或不耐受。芦曲泊帕中位治疗4(3~11)个月,中位随访8(6~11)个月。第3个月、第6个月及随访期末的治疗反应(OR)率分别为50.0%、58.3%和50.0%,OR中位起效时间2(1~4)个月;完全治疗反应(CR)率分别为8.3%、16.7%和16.7%,CR中位起效时间4(2~5)个月。不良反应均为Ⅰ级,发生率为25.0%。随访期间,1例停药后未能维持OR,复发率14.3%;未见克隆演变或死亡。提示芦曲泊帕对CsA难治性TD-NSAA患者有效且耐受性良好。.
引用
- Zhou YX, Wei YY, Liu ZW, et al. [Efficacy and safety of lusutrombopag monotherapy for cyclosporine A-refractory, transfusion-dependent non-severe aplastic anemia]. Zhonghua Xue Ye Xue Za Zhi. 2025. PMID: 41339051. doi:10.3760/cma.j.cn121090-20250225-00094
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。